Evidence map›Paper›PMID 31781503›Full record

ReviewFrontiers in oncology2019

Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma.

Xiangjun Tang, Shenqi Zhang, Rui Fu, Li Zhang, Kuanming Huang, Hao Peng, Longjun Dai, Qianxue Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022
    Review
  19. Review
  20. Advances in COVID-19 mRNA vaccine development.Signal transduction and targeted therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiangjun TangDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Shenqi ZhangDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Rui FuDepartment of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Li ZhangDepartment of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Kuanming HuangDepartment of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Hao PengDepartment of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Longjun DaiDepartment of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Qianxue ChenDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of glioblastoma has been a big challenge for decades in the oncological field mainly owing to its unique biological characteristics, such as high heterogeneity, diffusing invasiveness, and capacity to resist conventional therapies. The mRNA-based therapeutic modality holds many superior features, including easy manipulation, rapid and transient expression, and adaptive convertibility without mutagenesis, which are suitable for dealing with glioblastoma's complexity and variability. Synthetic anticancer mRNAs carried by various vehicles act as the ultimate attackers of the tumor across biological barriers. In this modality, specifically targeted glioblastoma treatment can be guaranteed by adding targeting molecules at certain levels. The choice of mRNA-bearing vehicle and administration method is a fully patient-tailored selection. This review covers the advantages and possible limitations of mRNA-based gene therapy, the

Indexed as

gene therapyglioblastomamRNApatient-tailoredtargeting molecules

Identifiers

PMID31781503
PMCPMC6857656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.